Results 51 to 60 of about 3,353 (184)

RESTORE-IMI 1: A Multicenter, Randomized, Doubleblind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections [PDF]

, 2020
Background. The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections. Methods.
Du, Jiejun, Joeng, Hee-Koung, Kaye, Keith S., Lyulko, Olexiy, Khan, Ireen, Stus, Viktor, Boucher, Helen W., Tipping, Robert W., Kartsonis, Nicholas A., Paschke, Amanda, Aggrey, Angela, Murta De Oliveira, Cláudia, File Jr, Thomas M., Brown, Michelle L., Young, Katherine, Motsch, Johann, Köksal, Iftihar, Butterton, Joan R.   +17 more
core   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa

mSphere, 2021
The growing emergence and spread of carbapenem-resistant pathogens worldwide exacerbate the clinical challenge of treating these infections. Given the importance of carbapenems for the treatment of infections caused by Pseudomonas aeruginosa , this study aimed to investigate the underlying genomic properties of the ...
Mario López-Pérez, Jose M. Haro-Moreno, Carmen Molina-Pardines, Maria Paz Ventero, Juan Carlos Rodríguez   +4 more
openaire   +4 more sources

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou, Jinqi Zhu, Ge Wu, Xi Kang, Qing Wang, Jie Liu, Yan Jiang   +6 more
wiley   +1 more source

Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study

, 2023
Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Ventero, Maria Paz, RODRIGUEZ DIAZ, JUAN CARLOS, Boix, Vicente, Sánchez Bautista, Antonia, DE HARO, JOSE MANUEL, García Rivera, Celia, Merino de Lucas, Esperanza, López-Pérez, Mario, Molina-Pardines, Carmen   +8 more
core   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari, Sepideh Elyasi, Farshad Abedi   +2 more
wiley   +1 more source

In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales from patients with intra-abdominal infections: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2020

Journal of Microbiology, Immunology and Infection, 2023
Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj   +1 more source

Emergence of Ceftazidime‐Avibactam‐Induced KPC Variants (KPC‐25/127) in Intracranial Infection and Implications for Clinical Management

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Novel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Ke Lei, Ying Tian, Chaoliang Xiong, Jing Lei, Dong Chen, Xiangni Bai, Mohd H. Abdul‐Aziz, Jiao Xie, Zeshi Liu   +8 more
wiley   +1 more source

Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Phage therapy shows promising efficacy against MDR, XDR, and PDR Pseudomonas aeruginosa infections across different models and administration routes. Evidence highlights reduced mortality, bacterial clearance, and synergy with antibiotics, while emphasizing the need for standardized protocols and advanced delivery systems to support clinical ...
Gustavo Aparecido da Cunha, Raine Piva Amaral, Ana Luisa Cauvila dos Santos, Bárbara Rafaela Ferreira Aio, Maria Fernanda Romboli Durante, Luiz Cosme Cotta Malaquias, Gabriel Magno de Freitas Almeida, Luiz Felipe Leomil Coelho   +7 more
wiley   +1 more source